GHK-Cu Research Overview: Structure, Models and Literature Themes

The GHK-Cu peptide sits at an unusual junction. It is a small, well characterized metal complex with decades of solution chemistry behind it, and its name also turns up on cosmetic ingredient lists. This profile stays with the laboratory record. For any individual batch, the analytical side lives in lot-matched certificates of analysis, where identity, copper content and lot number are recorded.

It follows the same compound profile pattern as the MOTS-c research overview and the Epitalon research overview, both published the same day and listed in the Journal archive.

Every finding below is labeled by study type, and no study amounts are restated.

What the GHK-Cu peptide is

GHK is the tripeptide glycyl-L-histidyl-L-lysine, with the molecular formula C14H24N6O4 in its PubChem record. The sequence places a free amino terminus next to a histidine imidazole ring, with lysine at the carboxyl end. Early papers abbreviate it GHL rather than GHK.

Loren Pickart’s group isolated the peptide from human plasma. In a 1980 report in Nature, the group noted that it co-isolated with roughly equimolar copper through several purification steps and proposed that it acts as a copper transport factor. The name GHK-Cu refers to the peptide with a bound Cu(II) ion.

These distinctions have practical weight. Two samples both labeled GHK-Cu can differ in copper ratio and counterion, and each difference shifts the expected analytical values.

How copper binds to GHK

GHK binds Cu(II) with high affinity, and the chemistry has been measured by several methods. Lau and Sarkar used potentiometric titration and visible absorption spectrophotometry across pH 3.5 to 10.6 and found multiple complex species in solution. In equilibrium dialysis experiments with equimolar albumin and peptide, about 42 percent of the Cu(II) was bound to the peptide. The authors discussed a possible role for such complexes in moving copper from blood to tissues. Both are in vitro solution chemistry results.

A follow up study from the same laboratory used NMR and EPR spectroscopy and described Cu(II) held by three nitrogen atoms and one oxygen atom in a square planar arrangement. Later work using isothermal titration calorimetry measured predominantly one to one binding, with a conditional dissociation constant of 7.0 × 10⁻¹⁴ M at pH 7.4.

For analysts, the working point is that GHK-Cu in solution is an equilibrium, not a fixed object. pH, competing ligands such as histidine, and the peptide to copper ratio all shift which species are present at a given moment.

What published GHK-Cu research examines

The research record is small and falls into a few study types. Each item below names the model and what was measured.

• Cell culture, copper uptake. In the same 1980 Nature report, the Pickart group found that the tripeptide formed complexes with copper(II) and increased copper uptake into cultured hepatoma cells. This is an in vitro finding.
• Gene expression, computational and in vitro. Campbell and colleagues profiled gene expression in lung tissue from smokers with COPD, then searched the Connectivity Map database for compounds whose expression profiles ran opposite to a signature linked to tissue destruction. GHK was one. In cultured human lung fibroblasts they measured gene expression, actin organization, integrin β1 and collagen gel contraction. No animal or human testing of GHK was part of the study.
• Animal model, wound chamber. Maquart and colleagues used a rat model in which stainless steel mesh cylinders were implanted under the skin. Chamber contents were analyzed for dry weight, total protein, collagen, DNA, glycosaminoglycans and collagen mRNA. The authors reported concentration dependent increases in these extracellular matrix measures compared with saline controls.
• Animal model and cell line, lung inflammation. Park and colleagues studied lipopolysaccharide exposure in RAW 264.7 macrophages and in C57BL/6 mice. They measured reactive oxygen species, superoxide dismutase activity, TNF-α and IL-6, NF-κB and MAPK signaling, lung histology and neutrophil markers, and reported lower inflammatory readouts in GHK-Cu groups than in lipopolysaccharide groups alone.

These studies share a pattern. Each measures molecular or tissue markers under controlled laboratory conditions. None of them measures an outcome in a person, and the conclusions belong to the authors of each paper.

What the GHK-Cu literature does not establish

The gaps are larger than the findings. Across the papers cited here, the evidence comes from solution chemistry, cultured cells, one computational screen and two rodent models.

• No established human findings. None of the studies profiled here tested GHK-Cu in people. Cell and rodent results do not translate into statements about human biology.
• Screening is not testing. A Connectivity Map match is a computational prediction drawn from expression data. It identifies a candidate for experiments and is not evidence of an effect in tissue.
• Species and form vary. Solution studies show several copper species depending on pH and competing ligands. A result obtained with one preparation cannot be assumed for material with a different copper ratio or counterion.
• Model markers are not outcomes. Collagen content in a rodent wound chamber and cytokine levels in a lipopolysaccharide model are laboratory measurements. They are not clinical endpoints.
• Cosmetic contexts are separate. The compound’s name appears in cosmetic ingredient contexts. That setting is outside this profile, and nothing here evaluates cosmetic claims of any kind.

Regulatory context shapes how any of this can be written. Under 21 CFR 201.128, intended use is judged by the objective intent of the people responsible for an article, shown through labeling claims, advertising and the circumstances of distribution. The Journal therefore describes study designs and measurements and stops there.

Reading a certificate for a GHK-Cu lot

A certificate of analysis is the document that ties a physical vial to analytical data. For a copper complex it has more to report than for a plain peptide, because both the peptide and the metal need to be accounted for.

Identity by mass is the first check. The observed mass should match the form stated on the certificate: free peptide, copper complex or salt. Copper content is the second, since a mass spectrum of the peptide alone does not show how much copper the lot carries. Appearance is the third. Cu(II) peptide complexes absorb visible light, so the appearance line should describe a colored solid rather than the white powder typical of an uncomplexed peptide.

• Lot number on the certificate matches the vial label
• Stated form names the peptide, the copper ratio and any counterion
• Observed mass agrees with the expected mass for that stated form
• Copper content is reported, with the method named
• Appearance describes a colored solid consistent with a copper complex
• HPLC result and chromatogram are attached for the same lot
• Testing laboratory and test date are identified

The quality and testing overview explains how Goated Peptides organizes lot testing, while the research use only policy and the compliance overview set out the terms that govern research material. Recurring documentation questions are answered in the site FAQ.

To see how these fields appear on a real document, look up a lot in the certificate library and check each item above against the record for that batch.

Frequently asked questions